(Reuters) - Mylan NV(MYL.O) has agreed to pay $96.5 million (£77.5 million) to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil ...
Canonsburg, Pa.-based Mylan will pay $96.5 million to settle a class-action lawsuit alleging it entered a “pay-to-delay” deal with the drugmaker Cephalon, reports Bloomberg. The lawsuit, filed by a ...
Mired in pay-for-delay lawsuits over its narcolepsy drug Provigil, Teva’s Cephalon is looking to clear the field. A class-action settlement in Pennsylvania could help ease investors’ minds. A federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results